Bioabsorbable Stents Market

Bioabsorbable Stents Market Outlook (2025 to 2035)

The global Bioabsorbable Stents Market is expected to reach USD 1,426.3 million by 2035, up from USD 490.9 million in 2024. During the forecast period 2025 to 2035, the industry is projected to register at a CAGR of 10.2%. The rising prevalence of coronary artery disease and the increasing preference for minimally invasive procedures are fueling demand for bioabsorbable stents. Their ability to naturally dissolve after restoring vessel patency eliminates long-term complications linked to permanent implants.

Metric	Value
Industry Size (2025E)	USD 540.0 million
Industry Value (2035F)	USD 1,426.3 million
CAGR (2025 to 2035)	10.2%

What are the drivers of bioabsorbable stents market?

The bioabsorbable stents market is experiencing a growing demand due to the rise in cardiovascular disease and a preference for easy-to-use technologies. Metallic stents may cause problems such as blocking the blood vessel over time and the risk of late clot formation. With BRS, vasomotion is restored over time, reducing the need for prolonged dual antiplatelet therapy.

Improvements in technology are also helping the market develop at a quicker pace. Healthcare costs are gradually increasing, more people are understanding heart health, and the number of interventional cardiology centers is expanding.

BSR support and clinical studies confirming the effectiveness of BRS are also important. Medtech businesses and startups are conducting trials to simplify the launch of their products in the market. The shift by global health systems toward value-based care is prompting people to opt for bioabsorbable stents, thereby expanding the market.

What are the regional trends of bioabsorbable stents market?

Due to the strong healthcare facilities and a high volume of research, North America is at the forefront of adopting new treatment strategies, making it the primary player in the bioabsorbable stents market. Many new stents are being used in the USA due to the increasing prevalence of coronary artery disease and the favorable reimbursement system.

Europe is behind only slightly, and Germany, the UK, and France have invested heavily in clinical research and procedures that are less invasive for the heart. Although some safety concerns have arisen in the past, the EU’s gradual acceptance of bioresorbable materials is encouraging their wider use.

The Asia Pacific population experiences the fastest rise because of new heart disease cases, an aging population and increased health investment. China and India are using advanced interventional treatments, since health access is improving, and companies from other countries are increasing their activities in the area.

At the same time, Latin America and the Middle East and Africa are slowly growing, mainly due to an increase in urban populations, the opening of more private hospitals, and greater awareness of heart health and treatments.

What are the challenges and restraining factors of bioabsorbable stents market?

Still, the bioabsorbable stent industry is experiencing many major obstacles. Mainly, caring about safety and how sound the results are, since it has been shown that older stents lead to more late blockages and failure in the treated area compared to standard drug-eluting stents. For this reason, interventional cardiologists are being careful about using these techniques.

It is also challenging due to stringent regulations. It takes the FDA and other agencies considerable clinical validation, which delays the release of new drugs and increases costs for producers. Because post-market surveillance requires a significant amount of time, it presents an additional challenge for companies to enter the market.

Surgeon training is crucial, as it significantly impacts the outcomes of bioabsorbable implantation procedures. Unless the long-term benefits are clearly shown, hospitals may not be ready to invest in BRS. Overcoming the doubts from previous failures is a key factor in realizing this market’s full potential.

Country-Wise Outlook

FDA-backed innovation and rising cardiac demand propel USA bioabsorbable stent market

USA has mature markets, a high rate of heart disease and good support for advanced heart surgery; bioabsorbable stents are highly valued. Since there are more than 800,000 coronary procedures each year, there is now a greater need for safer and better alternatives to metal stents. The use of bioabsorbable stents (BRS) offers a comprehensive solution for blood vessels, capturing the attention of cardiologists and their patients who prefer sustained benefits and fewer worries about complications.

Innovation is driven by the FDA-approved devices as well as by the company’s current clinical trials. More reimbursement programs now prefer therapies that deliver good results, such as BRS. Informing the public about heart disease prevention and less invasive surgeries is leading to more patients undergoing these procedures.

Policy-driven innovation and clinical leadership accelerate Germany’s bioabsorbable stent adoption

Germany leads the way in adopting bioabsorbable stents in Europe. Strong clinical research, well-equipped hospitals, and a supportive reimbursement framework, supported by the country's policy, stimulate a proactive approach to these first-class coronary intervention tools, whose use is on the rise. This is because, among other advantages, they promise complete vascular restoration and reduced long-term complications such as late stent thrombosis.

The Federal Joint Committee (G-BA) and statutory health insurance providers, further driving the inclusion of innovative cardiovascular devices in treatment protocols, support reimbursement for these devices. They are involved in multinational clinical trials and real-world evaluations, as are major cardiac centers located in cities such as Munich, Berlin, and Hamburg. Thus, the penetration into the market accelerated.

National policy and local innovation fuel China’s surge in bioabsorbable stent adoption

In China, the bioabsorbable stents market is growing because of a high burden of cardiovascular diseases, coupled with medical innovation policies, and a progressively more competitive environment for local organizations. Of those diseases, coronary artery disease ranks high among the killers in the country, and Healthy China 2030 should focus on modern interventional care under its national agenda and encourage any efforts to minimize rural-urban disparities in healthcare.

R&D investments are being made by Chinese companies, such as Lepu Medical and MicroPort, to locally manufacture lower-cost BRS, thus reducing dependence on imports. Foreign manufacturers, however, are creating a presence through joint ventures and regulatory partnerships. The National Medical Products Administration (NMPA) of China has been involved in reforms aimed at streamlining timelines and facilitating swift market access for cardiovascular technologies addressing high-unmet clinical needs.

Country Wise Insights

Countries	CAGR (2025 to 2035)
United States	6.2%
Germany	6.6%
China	9.9%

Category-Wise Analysis

Biodegradable innovation and clinical safety drive adoption of polymer-based stents

Stents made from bioabsorbable polymer are the most popular in the material segment because they are easy to dissolve in the body and safe to use. These stents are primarily made from PLA or PCL, allowing them to naturally degrade in the body, which reduces the risk of inflammation or blockage over time. Drug-eluting stents are mainly used for coronary artery diseases, in which scaffolding the artery is necessary for a short period. Stents temporarily hold the vessel in place during healing, and after the body has healed, they break down and let the vessel return to normal.

Even though supporters like the FDA and EMA are involved, the approval process requires a substantial amount of clinical evidence. Europe and North America are the primary regions where the technology is utilized due to their well-developed healthcare infrastructure and preference for the most effective devices. These stents are less harsh on the arteries than metal ones, and there are concerns about their longevity. New research and slimmer struts are making it possible to overcome these issues and get more global recognition for polymer stents.

Extended support and chronic care alignment elevate demand for slow-absorption stents

For those who need support for a long period due to severe problems in their arteries, slow-absorption stents are necessary. Typically, these stents have a slow degradation time, which helps the vessel heal properly and reduces the risk of the artery narrowing again after insertion. Their use is widespread among hospitals that handle cardiovascular care in North America and Western Europe.

If the material remains inside the vessel for an extended period, it may cause inflammation if not fully absorbed; therefore, more attention is given to improving materials and coatings. Even so, because they handle trials well, slow-absorption stents remain a good option for patients who are at high risk or who take a long time to heal. Improving bioresorbable materials should benefit patients and ensure that physicians are satisfied with the material's performance.

Temporary precision for lasting relief: Bioabsorbable stents transform coronary artery disease treatment

Coronary Artery Disease remains the largest segment of the global bioabsorbable stents market. CAD is considered a health crisis all over the world and is the main cause of death in older adults. Bioabsorbable stents are a great alternative to traditional DES, as they provide temporary support and medication and then dissolve over time, eliminating their permanent presence in the artery.

Cardiac surgery is being introduced in many European and North American hospitals due to tough cardiac care protocols and payment policies. Compared to DES, the results from clinical trials with CLL were not always positive; however, new therapies and drugs are addressing these issues. Timely checks are now being conducted after products are released to the market to ensure safety and effectiveness.

Competitive Analysis

The bioabsorbable stents market is characterized by strong competition stemming from advancements in technology, updates in regulations, and new medical findings. Organizations are exploring the use of magnesium and polymer mixtures to enhance the absorption of materials by the body, leading to better results for patients.

Cardiologists increasingly prefer and decide how to reimburse stents based on their ability to withstand expansion, their timeline to break down, and how they appear on scans. To appeal to those who need something other than metallic stents, companies are researching to prove that their devices are better suited for patients with different conditions and those who are young.

It remains challenging to enter this market, given the strict regulations and the requirement for companies to undertake long-term medical trials. Despite this, smaller companies and startups are growing in part by building partnerships, which save money and help them improve and update their inventions quickly. At the same time, expanding into the Asia-Pacific and Latin America is bringing more competition to the market, as these regions face a significant prevalence of heart disease. Efforts to develop stents with excellent degradation properties and a low risk of blood clots are still shaping the way this market grows.

Key players in the bioabsorbable stents industry include BIOTRONIK, Abbott Laboratories, REVA Medical, Inc., Elixir Medical Corporation, Arterial Remodelling Technologies S.A., Kyoto Medical Planning Co., Ltd., Microport Scientific Corporation, Arterius Ltd., and other notable players.

Recent Development

• In January 2025, BIOTRONIK announced the approval of two new indications for its Orsiro® Mission Drug-Eluting Stent (DES). The stent is now approved for one-month dual antiplatelet therapy (DAPT) in high bleeding risk patients and for use in patients with diabetes mellitus. These approvals expand the patient population that can benefit from the ultrathin strut bioabsorbable polymer-coated stent.
• In August 2024, the USA Food and Drug Administration (FDA) approved the Esprit BTK Everolimus Eluting Resorbable Scaffold System, marking a significant advancement in treating peripheral artery disease below the knee. This fully bioresorbable scaffold is designed to provide temporary support to the artery and then gradually dissolve, reducing long-term complications associated with permanent implants.

Methodology and Industry Tracking Approach

The 2025 global bioabsorbable stents market report by Fact.MR incorporates insights from 13,200 stakeholders across 33 countries, with a minimum of 325 respondents per market. 67% were end users or manufacturers, while 33% included regulatory experts, researchers, and procurement professionals. Between June 2024 and May 2025, data were collected on product demand, innovation, investment patterns, unmet needs, and risk factors along the value chain. Regional and demographic weighting ensured balanced representation.

The bioabsorbable stents market analysis references over 290 validated sources, including patents, academic papers, financial filings, and regulatory records. Advanced statistical techniques, including regression models, were employed to enhance accuracy.

Fact.MR has tracked the bioabsorbable stents market since 2018, focusing on its dynamics, trial performance, design breakthroughs, and commercialization hurdles, making the report a critical reference for strategic stakeholders.

Segmentation of Bioabsorbable Stents Market

• By Material :

  • Bioabsorbable polymer based stents
  • Bioabsorbable metallic stents

• By Absorption Rate :

  • Slow
  • Fast

• By Application :

  • Coronary Artery Diseases
  • Peripheral Artery Diseases

• By End User :

  • Hospitals
  • Cardiac Centers

• By Region :

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • East Asia
  • South Asia & Pacific
  • Middle East & Africa